Abramson Cancer Center of the Unviersity of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
NCT Number: NCT01809717
This study will establich the feasibility of weight lifting exercise among patients with multiple myeloma, determine if weight lifting exercise increases lean body mass among patients with multiple myeloma and obtain further preliminary data on toxicity and pharmacokinetics of high-dose melphalan.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Philadelphia, Pennsylvania, 19104, United States
This is a prospective, single-institution, pilot study of a 3 month weight lifting program designed to increase musle hypertrophy prior to starting stem cell collection and receiving high-dose melphalan, in patients with multiple myeloma. We will use this exercise intervention while patients are receiving initial induction chemotherapy in the 3-6 month period before they receiv high-dose melphalan. The primary study endpoint is to determine the feasibility of recruiting and retaining multiple myeloma patients to an exercise intervention trial. The secondary study endpoint is to determine whether the weight lifting program increases lean body mass as intended.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 3-6 months
Abramson Cancer Center at Penn Medicine
Other
Modulating The Toxicity And Efficacy Of High Dose Chemotherapy For Multiple Myeloma Through An Intervention To Increase Lean Body Mass
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01936532
Blood Protein Disorders, Cardiovascular Diseases
Bordeaux, France
View Trial DetailsNCT00405756
Newly Diagnosed Multiple Myeloma
South Brisbane, Queensland, Australia
View Trial DetailsNCT07709884
Carfilzomib, Newly Diagnosed Multiple Myeloma
Suzhou, Jiangsu, China
View Trial DetailsNCT05558319
Newly Diagnosed Multiple Myeloma
Alcalá de Henares, Madrid, Spain
View Trial Details